New Nurse Practitioner joins the practice

Maureen Strichman, ANP has joined our practice as a nurse practitioner. She has several years of experience as a nurse practitioner.  Prior to joining us, she worked in a busy orthopedic surgical practice where she performed  preoperative history and physicals, post operative appointments, corticosteroid and hyaluronic acid injections. She has also worked with headache patients and Alzheimer’s patients for neuropathic pain problems. She has had prior experience utilizing botulinum toxin Type A, in treating patients. We are thrilled to have Maureen on board here!

Dr. Edwards picture on the ACTRIMS 2018 registration email

The email blast for registration for ACTRIMS 2018 in San Diego has a picture of Dr. Edwards attending the conference from last year. He is the presenting author for this year for the abstract “Neuronal and glial CSF biomarkers in patients with secondary progressive multiple sclerosis treated with dimethyl fumarate” on February 1, 2018  Poster Session 1 in San Diego, CA

ACTRIMS 2018 email blast containing picture of Dr. Edwards

The above link containing photo on the right side has Dr. Edwards collaborating with a colleague.

From the Annual Meeting of the Consortium of MS Centers (CMSC), New Orleans

From Keith Edwards, MD   May 26, 2017

With the news of a MS patient in Germany who developed PML after 3 years of Tysabri and then one dose of ocrelizumab, the question of effectiveness and safety in ‘sequencing’ or switching from Tysabri (natalizumab) to another MS medication has become an even more important decision.  What is safe and yet effective to maintain stability in a MS patient who is at risk for PML after prolonged treatment with Tysabri has been a very important question for years.

Dr. Edwards presented a paper entitled: “Switching MS patients at risk for PML from natalizumab to teriflunomide:  Is it safe and effective?”

There is significant interest in this work among MS specialists to the extent that Dr Edwards’ research was referenced in the blog of 100 MS specialists this morning in a discussion about sequencing MS treatment.

Dr Edwards attended the CMSC meeting with 2 of the MS specialty infusion nurses from the MS Center in Latham, NY along with the nurse practitioner of the Center.  Besides presenting the above paper, Dr Edwards was co-author on 4 other papers involved with quality of life studies in MS.  The nurses and NP attended several conferences on the care of MS patients.

The MS Center of Northeastern New York, at 1205 Troy-Schenectady Road, Latham, is the only Comprehensive MS Care Center as recognized by the National MS Society in the greater Capital District.

Dr. Edwards and staff to attend CMSC, New Orleans

Dr. Edwards is the author/co-author on four posters – Accepted Abstracts  – at the CMSC Annual meeting in New Orleans, May 24-27. Karen Wesselhoeft, our nurse practitioner, has been accepted into the 9th Annual Linda Morgante Nurse Leadership Program from  May 22-24. Congratulations! Karen. Our infusion nurses, Samantha & Beverly are also attending the CMSC educational sessions to get the most up-to-date information to advance both clinical practice and research.


Dr. Edwards is author/co-author on several posters and platform presentations at AAN 2017

Dr. Edwards will be attending the 2017 American Academy of Neurology meeting in Boston, MA April 22-28. He is the author/co-author on several posters & platform sessions at AAN (Click here for accepted posters). The AAN Annual Meeting is the world’s largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to network, discuss cutting-edge research, and take part in top-rated education programming across a wide variety of topics.

FDA approves OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis

Roche announced as of March 28, 2017 that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The MS Center of Northeastern NY has participated in the Ocrelizumab clinical drug trials since 2011. We are the only center in the Capital region and beyond that has the expertise with ocrelizumab. Click here to see our latest advertisement on the Times Union.

MS Society Trial Alert lists the MS Center as an enrolling site for the Ocrelizumab studies.

National MS Society website for MS Trial Alerts dated March 6, 2017 & December 14,2016 regarding Ocrelizumab lists the MS Center of Northeastern NY in Latham, NY as a center enrolling patients for the two trials, OBOE & CHORDS. We are the only center in the Capital region and beyond that has experience with Ocrelizumab. Click here for more information.

Dr. Edwards’ poster presentation at ACTRIMS Forum 2017 in Orlando

Dr. Edwards attended the ACTRIMS Forum Meeting in Orlando, FL February 23-26, 2017. He was the first author on two posters at the ACTRIMS poster presentation on Thursday, February 23.( ACTRIMS 2017 posters ). The ACTRIMS Forum promised value to physicians, scientists, researchers, analysts, faculty, fellows and allied health professionals in examining the advances in research and treatment of MS on the care of patients. Dr. Edwards also got to network with some of the top researchers in the field of MS.